Evidence map›Paper›PMID 38483989›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Network of epistatic interactions in an enzyme active site revealed by large-scale deep mutational scanning.

Allison Judge, Banumathi Sankaran, Liya Hu, Murugesan Palaniappan, André Birgy, B V Venkataram Prasad, Timothy Palzkill

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Evolutionary rewiring of the dynamic network underpinning allosteric epistasis in NS1 of the influenza A virus.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. A combinatorially complete epistatic fitness landscape in an enzyme active site.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Allison JudgeVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX 77030.ORCID 0000-0003-4289-1748
Banumathi SankaranDepartment of Molecular Biophysics and Integrated Bioimaging, Berkeley Center for Structural Biology Lawrence Berkeley National Laboratory, Berkeley, CA 94720.
Liya HuVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX 77030.
Murugesan PalaniappanDepartment of Pathology and Immunology, Center for Drug Discovery, Baylor College of Medicine, Houston, TX 77030.ORCID 0000-0003-4916-6565
André BirgyVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX 77030.
B V Venkataram PrasadVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX 77030.ORCID 0000-0002-1172-2071
Timothy PalzkillVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX 77030.ORCID 0000-0002-5267-0001

Funding

User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6M
BETA-LACTAMASE MUTATIONS IN ANTIBIOTIC RESISTANCER01AI032956 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI Timothy Palzkill · 1992 to 2026
$6.5M
Beta Lactamase Mutations in Antibiotic ResistanceR37AI032956 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI PALZKILL, TIMOTHY · 2001 to 2010
$3.3M
Training Interdisciplinary Pharmacology ScientistsT32GM120011 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI DESSAUER, CARMEN W. · 2016 to 2020
$1.0M
Beta Lactamase Mutations in Antibiotic ResistanceR56AI032956 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI PALZKILL, TIMOTHY · 2016 to 2016
$394k
Development of a Precision Drug to target Y537S Mutant Estrogen Receptor in Metastatic Breast CancerR03CA259664 · NCI · BAYLOR COLLEGE OF MEDICINE · PI PALANIAPPAN, MURUGESAN · 2022 to 2023
$160k
NCI NIH HHS R03 CA259664NIAID NIH HHS R01 AI032956NIAID NIH HHS R37 AI032956NIAID NIH HHS R56 AI032956NIGMS NIH HHS P30 GM124169NIGMS NIH HHS T32 GM120011
6 · The paper itself

Abstract

Cooperative interactions between amino acids are critical for protein function. A genetic reflection of cooperativity is epistasis, which is when a change in the amino acid at one position changes the sequence requirements at another position. To assess epistasis within an enzyme active site, we utilized CTX-M β-lactamase as a model system. CTX-M hydrolyzes β-lactam antibiotics to provide antibiotic resistance, allowing a simple functional selection for rapid sorting of modified enzymes. We created all pairwise mutations across 17 active site positions in the β-lactamase enzyme and quantitated the function of variants against two β-lactam antibiotics using next-generation sequencing. Context-dependent sequence requirements were determined by comparing the antibiotic resistance function of double mutations across the CTX-M active site to their predicted function based on the constituent single mutations, revealing both positive epistasis (synergistic interactions) and negative epistasis (antagonistic interactions) between amino acid substitutions. The resulting trends demonstrate that positive epistasis is present throughout the active site, that epistasis between residues is mediated through substrate interactions, and that residues more tolerant to substitutions serve as generic compensators which are responsible for many cases of positive epistasis. Additionally, we show that a key catalytic residue (Glu166) is amenable to compensatory mutations, and we characterize one such double mutant (E166Y/N170G) that acts by an altered catalytic mechanism. These findings shed light on the unique biochemical factors that drive epistasis within an enzyme active site and will inform enzyme engineering efforts by bridging the gap between amino acid sequence and catalytic function.

Indexed as

beta-LactamasesEscherichia coliAmino Acid SubstitutionCatalytic DomainMutationbeta-Lactamasescooperativityenzyme evolutionenzyme mechanismepistasisfitness

Identifiers

PMID38483989
PMCPMC10962969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.